Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Trial Profile

Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Gonadotropin releasing hormone; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SPARE
  • Most Recent Events

    • 24 Jan 2018 Planned End Date changed from 1 Oct 2016 to 1 Oct 2018.
    • 24 Jan 2018 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2018.
    • 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top